Table I.

Summary of key points from the workshop.

Area	Key points	Supporting points
Overarching	Future PTOA trials are needed and supported	Early treatments that seek to prevent PTOA (i.e. around the time of injury) are likely to be feasible and acceptable with the right processes in place
Design of trials	It is important to have those who have experienced a knee injury, those with PTOA, and clinicians delivering care involved in trial design
	Approaches to stratification are supported in principle, but there are barriers to this that need to be addressed	The method of selecting those at ‘high’ and ‘low’ risk at the time of injury needs careful consideration
		Stratification using molecular data was seen as more acceptable than stratification based on demographic features such as sex, age, or modifiable factors like BMI
		The likely effect of the specific treatment target should be considered
		How we screen/enrol people for trials should be based on the person’s likelihood to respond to that treatment
		More work is needed to decide the choice and best use of preclinical models and human studies that establish molecular predictors of outcome, including mechanistic readouts of target response
New target development for trials	Improved understanding of disease pathology is supported to identify novel targets and enhance design of experimental medicine studies	Targeting symptoms as well as prevention of structural PTOA would be likely to increase appeal to younger patients

PTOA, post-traumatic osteoarthritis.